Phase 1-2a Dose-Ranging Study of TLK286 in Combination With Docetaxel in Platinum-Resistant Non-Small Cell Lung Cancer
Status:
Completed
Trial end date:
2004-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the effectiveness and safety of TLK286 given
intravenously once every three weeks in combination with docetaxel (Taxotere) in the
treatment of patients with non-small cell lung cancer that is resistant to platinum-based
chemotherapy.